A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

Scientists have found a breakthrough in the search for a cure for HIV, after research uncovered a development “previously thought impossible”. HIV can ‘hide’ itself in white blood cells, meaning the ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

The Gauteng Department of Health has strengthened its STI prevention strategy through targeted screening, outreach, and HIV ...